Trial Profile
Therapeutic effect of Peg-IFN therapy combined with RBV and telaprevir(TVR) on patients with chronic hepatitis C
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2014
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Apr 2014 New trial record